Jiangsu Hengrui Pharmaceuticals' Profit, Revenue Climb in 2025

MT Newswires Live03-26

Jiangsu Hengrui Pharmaceuticals' (SHA:600276, HKG:1276) profit attributable to owners rose to 7.71 billion yuan for 2025, from 6.34 billion yuan a year earlier, according to a Thursday Hong Kong bourse filing.

Earnings per share came in at 1.18 yuan, compared with 1.00 yuan a year earlier.

Analysts at Visible Alpha expected EPS of 1.26 yuan.

Revenue increased to 31.6 billion yuan from 28 billion yuan in 2024.

Analysts at Visible Alpha expected revenue of 32.4 billion yuan.

The board proposed a final dividend of 0.20 yuan per share, subject to shareholder approval, with payment expected within two months after the annual general meeting.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622881842?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-26 09:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622881842","market":"sh","top_or_hot":-1,"title":"Jiangsu Hengrui Pharmaceuticals' Profit, Revenue Climb in 2025","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/600276\">Jiangsu Hengrui</a> Pharmaceuticals' (SHA:600276, HKG:1276) profit attributable to owners rose to 7.71 billion yuan for 2025, from 6.34 billion yuan a year earlier, according to a Thursday Hong Kong bourse filing.</p><p>Earnings per share came in at 1.18 yuan, compared with 1.00 yuan a year earlier.</p><p>Analysts at Visible Alpha expected EPS of 1.26 yuan.</p><p>Revenue increased to 31.6 billion yuan from 28 billion yuan in 2024.</p><p>Analysts at Visible Alpha expected revenue of 32.4 billion yuan.</p><p>The board proposed a final dividend of 0.20 yuan per share, subject to shareholder approval, with payment expected within two months after the annual general meeting.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jiangsu Hengrui Pharmaceuticals' Profit, Revenue Climb in 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJiangsu Hengrui Pharmaceuticals' Profit, Revenue Climb in 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-26 09:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/600276\">Jiangsu Hengrui</a> Pharmaceuticals' (SHA:600276, HKG:1276) profit attributable to owners rose to 7.71 billion yuan for 2025, from 6.34 billion yuan a year earlier, according to a Thursday Hong Kong bourse filing.</p><p>Earnings per share came in at 1.18 yuan, compared with 1.00 yuan a year earlier.</p><p>Analysts at Visible Alpha expected EPS of 1.26 yuan.</p><p>Revenue increased to 31.6 billion yuan from 28 billion yuan in 2024.</p><p>Analysts at Visible Alpha expected revenue of 32.4 billion yuan.</p><p>The board proposed a final dividend of 0.20 yuan per share, subject to shareholder approval, with payment expected within two months after the annual general meeting.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2097828805.USD","symbol_name":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2622881842","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622881842","pubTimestamp":1774488267,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Jiangsu Hengrui Pharmaceuticals'  profit attributable to owners rose to 7.71 billion yuan for 2025, from 6.34 billion yuan a year earlier, according to a Thursday Hong Kong bourse filing.Earnings per share came in at 1.18 yuan, compared with 1.00 yuan a year earlier.Analysts at Visible Alpha expected EPS of 1.26 yuan.Revenue increased to 31.6 billion yuan from 28 billion yuan in 2024.Analysts at Visible Alpha expected revenue of 32.4 billion yuan.The board proposed a final dividend of 0.20 yuan per share, subject to shareholder approval, with payment expected within two months after the annual general meeting.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600276":"恒瑞医药","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","LU0359201885.HKD":"BGF CHINA \"A2\" (HKD) ACC","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","BK0060":"抗癌","01276":"恒瑞医药","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","LU1146622755.USD":"安本中国A股股票基金A Acc","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","BK0196":"行业龙头","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","BK0239":"医药制造","LU2289578879.USD":"ALLIANZ CHINA A OPPORTUNITIES \"AT\" (USD) ACC","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","LU1580142542.USD":"Blackrock Systematic China A-Share Opportunities A2 USD","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","LU2580892789.USD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (USD) ACC","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","BK0183":"MSCI概念","LU1997245177.USD":"安联神洲A股基金","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1255011170.USD":"JPM CHINA A-SHARE OPPORTUNITIES \"A\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU0359201612.USD":"贝莱德中国基金A2","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","BK0188":"融资融券","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","LU1655091616.SGD":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","BK0012":"证金概念","LU1781817850.SGD":"Blackrock Systematic China A-Share Opportunities A2 SGD-H","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","BK0028":"国家队","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","BK1191":"制药","LU2580892862.HKD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (HKD) ACC"},"translate_title":"江苏恒瑞医药2025年利润、营收攀升","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600276":0.9,"01276":0.9},"content_text":"Jiangsu Hengrui Pharmaceuticals' (SHA:600276, HKG:1276) profit attributable to owners rose to 7.71 billion yuan for 2025, from 6.34 billion yuan a year earlier, according to a Thursday Hong Kong bourse filing.Earnings per share came in at 1.18 yuan, compared with 1.00 yuan a year earlier.Analysts at Visible Alpha expected EPS of 1.26 yuan.Revenue increased to 31.6 billion yuan from 28 billion yuan in 2024.Analysts at Visible Alpha expected revenue of 32.4 billion yuan.The board proposed a final dividend of 0.20 yuan per share, subject to shareholder approval, with payment expected within two months after the annual general meeting.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622881842","isCrawlerRequest":true}